Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2021 Filed Feb 19, 2021 21:18 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Interven Cardio
|
Exercise / conversionDeferred Stock Units · Derivative | 3,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003159 · doc4.xml · derivative · entry 7 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,118 Underlying: Common Stock · 3,706 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F7 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F7 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:18 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Interven Cardio
|
Tax withholdingCommon Stock | 1,829 | $37.52 | $68,624.08 |
DisclosureSEC source: 0001225208-21-003159 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,930 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:18 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 3,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003159 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:18 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionDeferred Stock Units · Derivative | 2,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003160 · doc4.xml · derivative · entry 5 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,671 Underlying: Common Stock · 2,223 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:18 UTC |
Mackey Edward FEVP, Operations
|
Tax withholdingCommon Stock | 986 | $37.52 | $36,994.72 |
DisclosureSEC source: 0001225208-21-003160 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,406 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:18 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionCommon Stock | 2,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003160 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:16 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
Exercise / conversionDeferred Stock Units · Derivative | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003158 · doc4.xml · derivative · entry 5 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,336 Underlying: Common Stock · 1,111 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:16 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
Tax withholdingCommon Stock | 327 | $37.52 | $12,269.04 |
DisclosureSEC source: 0001225208-21-003158 · doc4.xml · nonDerivative · entry 2 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,904 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:16 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
Exercise / conversionCommon Stock | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003158 · doc4.xml · nonDerivative · entry 1 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:15 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionDeferred Stock Units · Derivative | 1,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003157 · doc4.xml · derivative · entry 5 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,559 Underlying: Common Stock · 1,853 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:15 UTC |
Carruthers WendySVP, Human Resources
|
Tax withholdingCommon Stock | 544 | $37.52 | $20,410.88 |
DisclosureSEC source: 0001225208-21-003157 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,080 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:15 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 1,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003157 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:15 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
Exercise / conversionDeferred Stock Units · Derivative | 2,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003156 · doc4.xml · derivative · entry 6 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,116 Underlying: Common Stock · 2,371 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:15 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
Tax withholdingCommon Stock | 1,006 | $37.52 | $37,745.12 |
DisclosureSEC source: 0001225208-21-003156 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,922 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:15 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
Exercise / conversionCommon Stock | 2,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003156 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:14 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionDeferred Stock Units · Derivative | 3,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003155 · doc4.xml · derivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,118 Underlying: Common Stock · 3,706 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:14 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 1,644 | $37.52 | $61,682.88 |
DisclosureSEC source: 0001225208-21-003155 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,091 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:14 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 3,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003155 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:25 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
GrantStock Option (Right to Buy) · Derivative | 20,368 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003183 · doc4.xml · derivative · entry 4 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,368 Underlying: Common Stock · 20,368 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:25 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
GrantRestricted Stock Units · Derivative | 6,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003183 · doc4.xml · derivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,333 Underlying: Common Stock · 6,333 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:25 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
GrantStock Option (Right to Buy) · Derivative | 27,873 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003182 · doc4.xml · derivative · entry 4 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,873 Underlying: Common Stock · 27,873 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:25 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
GrantRestricted Stock Units · Derivative | 8,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003182 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,666 Underlying: Common Stock · 8,666 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC |
Pierce David AEVP Pres MedSurg
|
GrantStock Option (Right to Buy) · Derivative | 42,881 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003181 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,881 Underlying: Common Stock · 42,881 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC |
Pierce David AEVP Pres MedSurg
|
GrantRestricted Stock Units · Derivative | 13,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003181 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 32,353 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001225208-21-003185 · doc4.xml · derivative · entry 6 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,353 shares Expires 2021-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase 32,353 shares of common stock vesting in full on March 7, 2015, the fourth anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
GrantStock Option (Right to Buy) · Derivative | 32,161 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003185 · doc4.xml · derivative · entry 5 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,161 Underlying: Common Stock · 32,161 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003185 · doc4.xml · derivative · entry 4 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 32,353 | $7.47 | $241,676.91 |
DisclosureSEC source: 0001225208-21-003185 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,398.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
GrantStock Option (Right to Buy) · Derivative | 19,296 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003184 · doc4.xml · derivative · entry 4 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,296 Underlying: Common Stock · 19,296 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003184 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC |
Olson ScottSVP & Pres, Rhythm Management
|
GrantStock Option (Right to Buy) · Derivative | 18,224 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003180 · doc4.xml · derivative · entry 4 Olson Scott · CIK 0001816850 · SVP & Pres, Rhythm Management 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,224 Underlying: Common Stock · 18,224 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC |
Olson ScottSVP & Pres, Rhythm Management
|
GrantRestricted Stock Units · Derivative | 5,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003180 · doc4.xml · derivative · entry 3 Olson Scott · CIK 0001816850 · SVP & Pres, Rhythm Management 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,666 Underlying: Common Stock · 5,666 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:21 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
GrantStock Option (Right to Buy) · Derivative | 27,873 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003178 · doc4.xml · derivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,873 Underlying: Common Stock · 27,873 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:21 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
GrantRestricted Stock Units · Derivative | 8,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003178 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,666 Underlying: Common Stock · 8,666 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
GrantStock Option (Right to Buy) · Derivative | 16,080 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003175 · doc4.xml · derivative · entry 4 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,080 Underlying: Common Stock · 16,080 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003175 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantStock Option (Right to Buy) · Derivative | 42,881 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003176 · doc4.xml · derivative · entry 4 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,881 Underlying: Common Stock · 42,881 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantRestricted Stock Units · Derivative | 13,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003176 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC |
Monson JonathanVP, Global Controller and CAO
|
GrantStock Option (Right to Buy) · Derivative | 14,299 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003177 · doc4.xml · derivative · entry 4 Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,299 Underlying: Common Stock · 14,299 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC |
Monson JonathanVP, Global Controller and CAO
|
GrantRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003177 · doc4.xml · derivative · entry 3 Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 235,849 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003174 · doc4.xml · derivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,849 Underlying: Common Stock · 235,849 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantRestricted Stock Units · Derivative | 73,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003174 · doc4.xml · derivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,333 Underlying: Common Stock · 73,333 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:18 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Interven Cardio
|
GrantStock Option (Right to Buy) · Derivative | 53,602 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003159 · doc4.xml · derivative · entry 6 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,602 Underlying: Common Stock · 53,602 shares Expires 2031-02-17 F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:18 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Interven Cardio
|
GrantRestricted Stock Units · Derivative | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003159 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2025-02-17 F4 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:18 UTC |
Mackey Edward FEVP, Operations
|
GrantStock Option (Right to Buy) · Derivative | 36,449 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003160 · doc4.xml · derivative · entry 4 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,449 Underlying: Common Stock · 36,449 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:18 UTC |
Mackey Edward FEVP, Operations
|
GrantRestricted Stock Units · Derivative | 11,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003160 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,333 Underlying: Common Stock · 11,333 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:16 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
GrantStock Option (Right to Buy) · Derivative | 19,296 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003158 · doc4.xml · derivative · entry 4 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,296 Underlying: Common Stock · 19,296 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:16 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003158 · doc4.xml · derivative · entry 3 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:15 UTC |
Carruthers WendySVP, Human Resources
|
GrantStock Option (Right to Buy) · Derivative | 28,945 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003157 · doc4.xml · derivative · entry 4 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,945 Underlying: Common Stock · 28,945 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:15 UTC |
Carruthers WendySVP, Human Resources
|
GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003157 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.